Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1963 1
1965 1
1966 2
1968 3
1969 3
1970 1
1971 3
1972 1
1973 2
1974 2
1975 1
1976 6
1977 2
1978 1
1979 1
1980 1
1981 1
1982 8
1983 2
1985 5
1986 4
1987 2
1988 6
1989 10
1990 8
1991 10
1992 6
1993 8
1994 8
1995 8
1996 16
1997 6
1998 8
1999 9
2000 15
2001 15
2002 14
2003 27
2004 10
2005 22
2006 7
2007 7
2008 22
2009 11
2010 14
2011 17
2012 18
2013 17
2014 19
2015 21
2016 9
2017 23
2018 20
2019 15
2020 23
2021 33
2022 35
2023 36
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

567 results

Results by year

Filters applied: . Clear all
Page 1
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC; STEP-HFpEF Trial Committees and Investigators. Kosiborod MN, et al. Among authors: moller dv. N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25. N Engl J Med. 2023. PMID: 37622681 Clinical Trial.
Sarcoidosis.
Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Müller-Quernheim J. Grunewald J, et al. Among authors: moller dr. Nat Rev Dis Primers. 2019 Jul 4;5(1):45. doi: 10.1038/s41572-019-0096-x. Nat Rev Dis Primers. 2019. PMID: 31273209 Review.
The mechanisms of action of PPARs.
Berger J, Moller DE. Berger J, et al. Among authors: moller de. Annu Rev Med. 2002;53:409-35. doi: 10.1146/annurev.med.53.082901.104018. Annu Rev Med. 2002. PMID: 11818483 Review.
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, Hovingh KG, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Petrie MC. Kosiborod MN, et al. Among authors: moller dv. JACC Heart Fail. 2023 Aug;11(8 Pt 1):1000-1010. doi: 10.1016/j.jchf.2023.05.010. Epub 2023 May 21. JACC Heart Fail. 2023. PMID: 37294245 Free article. Clinical Trial.
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Hallakou-Bozec S, et al. Among authors: moller de. Diabetes Obes Metab. 2021 Mar;23(3):664-673. doi: 10.1111/dom.14277. Epub 2020 Dec 29. Diabetes Obes Metab. 2021. PMID: 33269554 Free PMC article. Review.
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ; STEP-HFpEF DM Trial Committees and Investigators. Kosiborod MN, et al. Among authors: moller dv. N Engl J Med. 2024 Apr 18;390(15):1394-1407. doi: 10.1056/NEJMoa2313917. Epub 2024 Apr 6. N Engl J Med. 2024. PMID: 38587233 Clinical Trial.
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, Einfeldt MN, Hovingh GK, Møller DV, Petrie MC, Shah SJ, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Núñez J, Perna E, Schou M, Senni M, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN. Borlaug BA, et al. Among authors: moller dv. Nat Med. 2023 Sep;29(9):2358-2365. doi: 10.1038/s41591-023-02526-x. Epub 2023 Aug 27. Nat Med. 2023. PMID: 37635157 Free PMC article.
Role of AMP-activated protein kinase in mechanism of metformin action.
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Zhou G, et al. Among authors: moller de. J Clin Invest. 2001 Oct;108(8):1167-74. doi: 10.1172/JCI13505. J Clin Invest. 2001. PMID: 11602624 Free PMC article.
Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.
Nørgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Møller DV, Knudsen LB, Kvist K, Zinman B, Holm E, Torp-Pedersen C, Mørch LS. Nørgaard CH, et al. Among authors: moller dv. Alzheimers Dement (N Y). 2022 Feb 23;8(1):e12268. doi: 10.1002/trc2.12268. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35229024 Free PMC article.
567 results